



# Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children

Julia Roider<sup>1,2,3,4,5</sup>, J. Zachary Porterfield<sup>1,6</sup>, Paul Ogongo<sup>1,7,8</sup>, Maximilian Muenchhoff<sup>2,3,5,9</sup>, Emily Adland<sup>2</sup>, Andreas Groll<sup>10</sup>, Lynn Morris<sup>11,12,13</sup>, Penny L. Moore<sup>11,12,13</sup>, Thumbi Ndung'u<sup>1,3,14,15,16</sup>, Henrik Kløverpris<sup>1,14,17</sup>, Philip J. R. Goulder<sup>2</sup> and Alasdair Leslie<sup>1,14\*</sup>

<sup>1</sup> Africa Health Research Institute (AHRI), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa, <sup>2</sup> Department of Paediatrics, University of Oxford, Oxford, United Kingdom, <sup>3</sup> HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa, <sup>4</sup> Department of Infectious Diseases, Ludwig-Maximilians-University, Munich, Germany, <sup>5</sup> German Center for Infection Research (DZIF), Munich, Germany, <sup>6</sup> School of Public Health, Yale University, New Haven, CT, United States, <sup>7</sup> School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa, <sup>8</sup> Institute of Primate Research, National Museums of Kenya, Nairobi, Kenya, <sup>9</sup> Faculty of Medicine, Virology, National Reference Center for Retroviruses, Max von Pettenkofer Institute, LMU München, Munich, Germany, <sup>10</sup> Faculty of Statistics, TU Dortmund University, Dortmund, Germany, <sup>11</sup> Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa, <sup>12</sup> Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, <sup>13</sup> Center for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa, <sup>14</sup> Department of Infection and Immunity, University College London, London, United Kingdom, <sup>15</sup> Virology and Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, <sup>16</sup> The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, MA, United States, <sup>17</sup> Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark

## OPEN ACCESS

### Edited by:

Francesca Chiodi,  
Karolinska Institute (KI), Sweden

### Reviewed by:

Gabriella Scarlatti,  
San Raffaele Hospital (IRCCS), Italy  
Monica Vaccari,  
National Institutes of Health (NIH),  
United States

### \*Correspondence:

Alasdair Leslie  
al.leslie@ahri.org

### Specialty section:

This article was submitted to  
Viral Immunology,  
a section of the journal  
Frontiers in Immunology

**Received:** 29 March 2019

**Accepted:** 14 June 2019

**Published:** 02 July 2019

### Citation:

Roider J, Porterfield JZ, Ogongo P, Muenchhoff M, Adland E, Groll A, Morris L, Moore PL, Ndung'u T, Kløverpris H, Goulder PJR and Leslie A (2019) Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children. *Front. Immunol.* 10:1497. doi: 10.3389/fimmu.2019.01497

Children may be the optimal target for HIV vaccine development as they generate substantially more frequent and more potent broadly HIV neutralizing antibodies (bnAbs) than adults. Development of a biomarker that correlates with neutralization breadth in this group could function as a powerful tool to facilitate the development of an HIV vaccine. Previously, we observed that this preferential ability in HIV-infected children over adults to generate bnAbs is associated with an enrichment of circulating follicular helper T-cells (T<sub>FH</sub>) with an effector phenotype, and the presence of IL-21 secreting HIV-specific T<sub>FH</sub> within lymphoid tissue germinal centers (GC). In adults, bnAbs development has been linked with high plasma levels of CXCL13, a chemoattractant for CXCR5-expressing T<sub>FH</sub> cells to the lymph node GC. We sought to test this relationship in HIV-infected children, but found no association between neutralization breadth and plasma levels of CXCL13, or with the Th2 cytokines IL-4 and IL-13, or the T<sub>FH</sub> associated factor Activin A. However, we did find an unexpected association between plasma IL-5 levels and bnAb development in these children. Importantly, although CXCL13 correlated with total circulating T<sub>FH</sub> cells, it was not associated with effector T<sub>FH</sub>. Additionally, raised CXCL13 expression was associated with a lower CD4 percentage, higher viral load and a loss of immune function, implying it is associated with progressive disease rather than HIV-specific GC activity in these subjects. Taken together, our data suggests that IL-5 should be evaluated further as a candidate plasma biomarker for HIV neutralization breadth and for monitoring vaccine responses in the pediatric age group.

**Keywords:** CXCL13, IL-5, Activin A, broadly neutralizing antibodies (bnAbs), pediatric HIV, plasma markers, HIV neutralization breadth, T-follicular helper cells (T<sub>fh</sub>)

## INTRODUCTION

Recent HIV vaccine development strategies have highlighted the unique potential contribution that can be made by the study of the immune responses to HIV infection in children (1). In response to the same gp120 vaccine, infants produced higher magnitude anti-V1V2 antibodies than adults (2). Furthermore, there is growing evidence that children are better at eliciting HIV-specific antibody responses than adults and develop broad and potent neutralizing antibodies as early as 2 years of life (3, 4). Although the mechanistic details are not fully established, the immune system in early life is specifically adapted, via the support and regulation of T<sub>FH</sub> activity, to high frequency, high affinity antibody production (5, 6).

Germinal centers (GC) of secondary lymphoid organs are the primary site where a humoral immune response develops, but are challenging to directly monitor in vaccine trials due to a lack of routine access to lymphoid tissue. Recent attempts to use fine needle aspirates show promise (7), but this invasive technique is unlikely to be adopted for children. As an alternative various studies of plasma markers of germinal center activity have been conducted in adults to seek for correlates to GC activity (8–10).

T-follicular helper cells (T<sub>FH</sub>) are key regulators of the antibody immunity, as they are critical for the formation of GCs and for the development of high-affinity antibodies and memory B cells. They restrict access to GCs for low-affinity B cells, promote the survival of high-affinity B cells and trigger B cell receptor (BCR) signaling. Crucially, signaling from T<sub>FH</sub> cells drives the extensive somatic hypermutation necessary for the generation of broadly neutralizing antibodies to HIV (11–13). Although T<sub>FH</sub> cells mainly function in secondary lymphoid tissue, they are also present in circulation and have been associated with HIV neutralization breadth in adult (14) and pediatric (6) infection. However, it remains unclear how the frequency and phenotype of these cells in circulation reflects their activity within the GC. Moreover, we have previously reported the presence of high frequency IL-21 producing HIV-specific GC T<sub>FH</sub> in lymphoid tissue of HIV-infected children that are not readily detected in circulation (6). An alternative approach is to study plasma markers that might correlate with T<sub>FH</sub> activity within the GC. The CXCL13–CXCR5 chemokine axis, for example, plays a central role in organizing both B-cell follicles and GCs, as CXCR5 expressing T<sub>FH</sub> cells use CXCL13 to migrate into the GCs of secondary lymphoid tissue (15). In adults, it has been reported that plasma CXCL13 levels during early HIV infection can predict the generation of broadly neutralizing antibodies in chronic disease (8, 10). Additionally, elevated plasma levels of CXCL13 have been observed in HIV-infected individuals with high neutralization breadth (9). Additionally, a positive correlation between circulating T<sub>FH</sub> and plasma CXCL13 levels has been observed in HIV-infected children (16). However, whether CXCL13 correlates with GC activity or the development of bnAbs against HIV in children is unknown. Using a previously described cohort of HIV-infected children, in whom the frequent development of bnAbs was associated with the T<sub>FH</sub> response (6), we therefore tested the potential role of CXCL13 as a biomarker of increased T<sub>FH</sub> activity and neutralization breadth. In addition, we measured other candidate plasma markers of T<sub>FH</sub> activity:

Activin A has been identified as a powerful regulator of the differentiation of T<sub>FH</sub> cells, which is antagonized by IL-2 (17); and the Th2 cytokines IL-13, IL-4, and IL-5. The latter two have been described as important stimulators of the GC reaction (18), and impaired IL-5 production by T-cells has been previously described as a prognostic marker of disease progression in HIV-infected children (19).

## MATERIALS AND METHODS

### Study Participants

Plasma and peripheral blood mononuclear cells (PBMC) of 45 vertically HIV-1 C clade-infected ART-naïve children with matched neutralization data (4) and of pediatric uninfected controls ( $n = 7$ ) were studied. All children were recruited from South African clinics at Kimberley Hospital (Kimberley, South Africa) and Ithembalabantu Clinic (Durban, South Africa). Uninfected controls were from the same ethnical background, being mostly siblings of infected study participants. Notably, the uninfected controls available for this study were significantly older than the HIV-infected children studied (13–16.5 vs. 5.7–10.8 years old). The clinical characteristics of the study cohort are shown in **Table 1**. “High” neutralizers were defined by neutralization of  $\geq 81\%$  of tested viruses ( $\geq 75\%$  percentile;  $n = 13$ ) and “low” neutralizers by neutralization of  $\leq 44\%$  of tested viruses ( $\leq 25\%$  percentile;  $n = 13$ ). Viral load measurements were performed as described previously (4). Informed consent was obtained from all adult study participants or from the caregivers of pediatric participants where appropriate. Additionally, assent to participate in the study was given directly by children from the age of 6 and above. Studies were approved by the University of the Free State Ethics Committee, Bloemfontein; Biomedical Research Ethics Committee, University of KwaZulu-Natal, Durban; and Research Ethics Committee, University of Oxford.

### Sample Processing—PBMC and Plasma

Plasma was separated by centrifugation and cryopreserved at  $-80^{\circ}\text{C}$ . PBMCs were isolated by Ficoll density gradient centrifugation and stored in liquid nitrogen until use.

### Virus Neutralization Assays

The ability of plasma from infected children to neutralize HIV was measured against a panel of 16 tier 2 and tier 3 clade A, B, and C viruses. Neutralization was determined by a reduction in luciferase gene expression after a single round of infection of JC53bl-13 cells, also known as TZM-bl cells (National Institutes of Health AIDS Research and Reference Reagent Program), with Env-pseudotyped viruses as previously described (4). Titer was calculated as the reciprocal plasma/serum dilution causing a 50% reduction of relative light units [median infective dose (ID<sub>50</sub>)].

### Flow Cytometry and ICS Assays

PBMCs obtained at the same time point as plasma were stained with fluorescent monoclonal antibodies against markers associated with T<sub>FH</sub> cells as previously described (6). For a subset of this cohort ( $n = 18$ ), intracellular cytokine staining assays for IL-4 (BD, FITC, 554484), IL-5 (BD, APC, 554397), IL-13 (BD, V450, 561158), TNF- $\alpha$  (BD, AF700, 557996), and

**TABLE 1** | Clinical characteristics of study cohort.

Group	<i>n</i>	Age median (IQR)	CD4/mm <sup>3</sup> median (IQR)	VL cp/ml median (IQR)	Neutralization breadth (IQR)
Pediatric infected	45	7.6 (6.1–9.8)	790 (309–1067)	42,000 (14,000–132,834)	63 (44–81)
high neutralizers (high)	13	9.6 (6.6–10.8)	662 (315–1021)	62,000 (17,184–104,712)	88 (81–97)
low neutralizers (low)	13	7.0 (5.7–10.2)	1039 (806–1101)	37,207 (7080–194,243)	38 (22–44)
Pediatric uninfected	7	15.0 (13.0–16.5)	N/A	N/A	N/A

N/A not applicable

INF- $\gamma$  (BD, PE-Cy7, 557643) were performed. Briefly, cells were stimulated with PMA/Ionomycin (at a final concentration of  $4 \times 10^{-5}$  M) in the presence of anti-CD28 and anti-CD49 (1 mg/ml), Brefeldin A and Monensin (5 mg/ml) (BD biosciences) for 5 h, followed by surface staining and intracellular staining. Rainbow beads (BD biosciences) were run with every experiment and compensation was adjusted to ensure longitudinal comparability of experiments. Flow cytometry acquisition was performed on a BD LSRFortessa within 5 h of staining and analyzed using FlowJo version 9.9.5.

## Plasma Assays

Plasma markers and neutralization breadth were determined in matching time points in vertically infected children for all available samples. *Ex-vivo* plasma levels of IL-5 were quantified using a commercially available Luminex kit for human cytokine/chemokine (Milliplex). Plasma samples were tested in duplicate per the manufacturer's recommendations. Plasma levels of CXCL13 were quantified using a commercially available enzyme-linked immunosorbent assay kit (R&D Systems) in duplicate. Plasma levels of IL-4 and IL-13 were quantified using high sensitivity ELISA kits from Invitrogen and Activin A and IL-2 using ELISA kits from Sigma Aldrich.

## Statistical Analysis

Statistical analyses were performed using Prism GraphPad Software version 8.0.2 and the statistical software R (20). After confirming a non-Gaussian distribution within the majority of the parameters analyzed, the Wilcoxon-Mann-Whitney test was used to compare continuous factors between two groups. Correlation analyses were performed using the Spearman rank correlation method with exact permutation *p*-values calculated. All *p*-values are two-sided, and a *p*-value of  $< 0.05$  was considered significant. In scatterplots, median values are indicated. To analyse the effect of the plasma markers measured (IL-4, IL-13, IL-5, CXCL13, Activin A, IL-2) on neutralization breadth, we use a generalized linear model assuming a Poisson distribution (21, 22).


## RESULTS

### Plasma CXCL13 Correlates With Disease Progression but Not Neutralization Breadth in HIV-Infected Children

To characterize potential plasma correlates of neutralization breadth, we first measured plasma CXCL13, a proposed marker

of GC activity (9), in a cohort of antiretroviral (ART) naïve, HIV-infected children ( $n = 45$ ) with available neutralization data from matching time points (4) (Table 1). In contrast to previous reports in adults (9), plasma CXCL13 were not correlated with HIV neutralization breadth when considering all individuals; or when comparing individuals in the top quartile of neutralizers (who neutralized  $\geq 81\%$  of tested viruses; "high neutralizers") to those in the bottom quartile (who neutralized  $\leq 44\%$  neutralization breadth; "low neutralizers"; Figure 1A and Table 1). However, we did observe a correlation between the frequency of total blood T<sub>FH</sub> cells (defined as CD3<sup>+</sup>CD4<sup>+</sup>CD45RA<sup>-</sup>CXCR5<sup>+</sup>CXCR3<sup>-</sup>PD1<sup>+</sup> lymphocytes) and CXCL13 plasma levels ( $r = 0.44$ ,  $p = 0.004$ ; Figure 1B) within the whole pediatric cohort, including HIV-ve controls, suggesting a potential association between these parameters. Previously we observed that circulating effector T<sub>FH</sub> cells (CCR7<sup>-</sup>) were associated with neutralization breadth, but central T<sub>FH</sub> cells (CCR7<sup>+</sup>) were not (6). Examining these groups we find a correlation between CXCL13 and central T<sub>FH</sub> cells ( $r = 0.43$ ,  $p = 0.006$ ), but not the functional effector T<sub>FH</sub> subset (Figure 1C), consistent with lack of association between CXCL13 and neutralization breadth. Moreover, when excluding HIV uninfected children we find no significant associations between CXCL13 and any T<sub>FH</sub> subset. We next examined markers of disease progression and found that plasma CXCL13 was directly correlated with plasma viral load ( $r = 0.34$ ;  $p = 0.008$ ; Figure 1D) and inversely correlated with CD4 percentage ( $r = -0.5$ ;  $p = 0.0006$ ; Figure 1E) and CD4 count (data not shown). Together these data suggest that, in HIV-infected children, CXCL13 plasma levels do not correlate with GC activity or T<sub>FH</sub> functionality, but rather with HIV disease progression.

To further investigate this association, we assessed CD4 T-cell functionality in a subset of our cohort, for whom samples were available, by stimulating PBMCs with PMA/Ionomycin and measuring cytokine production in CD4 T-cells by intracellular cytokine staining. We observe a strong inverse correlation between the frequencies of cells producing the Th2 cytokines IL-4 and IL-13 and plasma CXCL13 (Figure 1F). Similar trends were also detected for TNF- $\alpha$  and INF- $\gamma$  (Supplementary Figure S1), and maintained when only considering HIV-infected children (data not shown). Overall these data support the hypothesis that, in HIV-infected children CXCL13 is not a good marker of GC activity, but is rather associated with disease progression and loss of immune function.




**FIGURE 1 |** Plasma CXCL13 does not correlate with neutralization breadth in HIV-infected children. **(A)** Left: No correlation between plasma CXCL13 and neutralization breadth at matching time points in a cohort of HIV-infected children ( $n = 45$ ). Right: No differences in plasma CXCL13 levels between children with high neutralization breadth (neutralization of  $\geq 81\%$  of viruses tested or  $\geq 75\%$  percentile;  $n = 13$ ) and children with low neutralization breadth (neutralization of  $\leq 44\%$  of viruses tested or  $\leq 25\%$  percentile;  $n = 13$ ). **(B)** Positive correlation between plasma CXCL13 and frequencies of circulating T-follicular helper cells ( $T_{FH}$ ;  $CD4^+ CD45RA^- CXCR5^+ CXCR3^- PD1^+$ ) in children including HIV-ve controls with available samples (infected:  $n = 33$ ; uninfected:  $n = 7$ , green dots) ( $p = 0.004$ ,  $r = 0.44$ ) (Table 1). **(C)** Circulating  $T_{FH}$  cells were further subdivided into circulating central  $T_{FH}$  cells ( $CCR7^+$ ; left) and circulating effector  $T_{FH}$  cells ( $CCR7^-$ ; right). Central  $T_{FH}$  cells but not effector  $T_{FH}$  cells were found to correlate significantly with CXCL13. **(D)** Positive correlation between CXCL13 and viral load and **(E)** an inverse correlation with CD4 percentage was observed in HIV-infected children ( $n = 45$ ). **(F)** Inverse correlations between IL-13 and IL-4 production by bulk CD4 T cells using intracellular cytokine staining assays in response to PMA/ionomycin stimulation in a subgroup of children including HIV-ve controls (infected:  $n = 12$ ; uninfected  $n = 6$ , green dots) with available data. For comparison between 2 groups, Mann-Whitney tests were performed. Medians are indicated in scatter plots as a solid black line. Calculation of correlations were made by Spearman's rank correlation test.

### Plasma IL-5 Correlates With Neutralization Breadth in HIV-Infected Children

Having observed an association between plasma CXCL13 and the frequency of IL-4/IL-13 secreting CD4 T-cells, we next measured *ex-vivo* plasma levels of these cytokines and another canonical Th2 cytokine, IL-5, and determined their association with neutralization breadth. Surprisingly, of these cytokines only

IL-5, (Figure 2A) but not IL-4 and IL-13 (Figures 2B,C), was elevated in children with high neutralization breadth ( $\geq 75\%$  percentile, neutralization of  $\geq 81\%$  of viruses tested,  $n = 13$ ) compared to those with low neutralization breadth ( $\leq 25\%$  percentile, neutralization of  $\leq 44\%$  of viruses tested,  $n = 13$ ) ( $p = 0.01$ ). This corresponded with a positive correlation between plasma IL-5 and neutralization breadth in HIV-infected



children ( $r = 0.3$ ,  $p = 0.02$ ). To account for multiple statistical comparisons, we conducted a multivariate Poisson regression model analysis for all cytokines measured, and confirmed a significant positive association between plasma IL-5 and neutralization breadth ( $p = 0.0038$ ). There was, however, no correlation between plasma IL-5 and any of the circulating  $T_{FH}$  subsets or plasma CXCL13 (Supplementary Figure S2A) and overall little IL-5 production of CD4 T-cells when stimulated with PMA/ Ionomycin in a subset of the cohort with available samples (Supplementary Figure S2B). In conclusion, plasma IL-5, but not IL-4 or IL-13, correlates with neutralization breadth in HIV-infected children.

## No Association Between Plasma Activin a and Neutralization Breadth in HIV-Infected Children


Finally, we assessed a novel cytokine associated with  $T_{FH}$  activity, Activin A. This molecule has been demonstrated to be a potent

activator of  $T_{FH}$  differentiation through a mechanism that is antagonized by IL-2 (17). We therefore measured plasma levels of both Activin A and IL-2 in our cohort of HIV-infected children. To our knowledge, Activin A levels have not been assessed in HIV-infected individuals and the impact of disease on this cytokine was unknown. All individuals had high levels of Activin A in their plasma, ranging between 2133 and 16,088 pg/ml. Production of this cytokine may be altered by HIV infection as plasma levels correlated weakly with CD4% and a similar trend was observed for CD4 count (data not shown). However, this did not reach significance and no correlation with VL was observed (Figure 3A). Importantly, although there is a broad range of Activin A expression, we observed no correlation with neutralization breadth in the cohort as a whole, and no significant difference in Activin A levels between the top 25% (high) and the bottom 25% (low) of subjects based on neutralization breadth (Figure 3B). Because effect of Activin A on  $T_{FH}$  is reported to be antagonized by IL-2, we also tested the association between the ratio of IL2:Activin A and neutralization breadth and found no correlation (Figure 3C). Moreover, plasma IL-2 alone does not correlate with neutralization breadth (Figure 3D). Finally, there was no correlation between either Activin A or IL-2 and plasma levels of CXCL13 suggesting these cytokines are not co-regulated (Figure 3E).

## DISCUSSION

The immune responses of children offer some unique perspectives that have the potential to inform HIV vaccine efforts (1). A protective HIV vaccine will most likely require the generation of bnAbs and this depends on both an effective GC response and  $T_{FH}$  activity. Since direct monitoring of the GC response in future pediatric vaccine trials is not feasible due to lack of routine access to tissue, a plasma marker of the GC response,  $T_{FH}$  activity, and neutralization breadth would be of great value. While in adults plasma CXCL13 levels during early HIV infection can predict the generation of bnAbs in chronic disease stage (8, 10) and individuals with high neutralization breadth show elevated CXCL13 levels (9), this had not previously been examined in pediatric patients.

Our observations that plasma CXCL13 correlated with disease progression and general immune activation in pediatric patients rather than with neutralization breadth is in line with previously published findings where plasma CXCL13 was elevated in adults with progressive HIV infection and correlated with the inflammation-associated chemokine IP-10 (23). Furthermore, plasma CXCL13 levels were elevated in HIV-infected children compared to HIV-ve controls and correlated with viral load in infected children (16, 24). In adults, bnAb development is linked with viral loads and therefore with disease progression (25), whereas in pediatrics bnAb development is also facilitated by functional T-follicular helper and regulatory responses in the setting of persistent high viremia (4, 6). Additionally, plasma CXCL13 has been associated with immune activity in various infectious and autoimmune diseases (23, 26–30), suggesting that it may not be a specific marker of germinal center activity. This



**FIGURE 3 |** No association between plasma Activin A and neutralization breadth in HIV-infected children. **(A)** Left: Correlation between CD4% and plasma Activin A and Right: Lack of correlation between plasma Activin A and viral load in HIV-infected children ( $n = 39$ ). **(B)** Left: No correlation between plasma Activin A and neutralization breadth in the same cohort. Right: No differences in plasma Activin A levels between children with high neutralization breadth (neutralization of  $\geq 81\%$  of viruses tested or  $\geq 75\%$  percentile;  $n = 13$ ) and children with low neutralization breadth (neutralization of  $\leq 44\%$  of viruses tested or  $\leq 25\%$  percentile;  $n = 13$ ). **(C)** Lack of correlation between neutralization breadth and the ratio of plasma IL-2:Activin A ( $n = 39$ ). **(D)** Left: No correlation between IL-2 levels and neutralization breadth ( $n = 39$ ). Right: No differences in plasma IL-2 levels between children with high ( $n = 13$ ) and low neutralization breadth ( $n = 13$ ). **(E)** Left: No correlation between plasma Activin A and plasma CXCL13. Middle: No correlation between IL-2 and CXCL13 in plasma. Right: No correlation between plasma IL-2 and plasma Activin A levels ( $n = 39$ ). For comparison between 2 groups, Mann-Whitney tests were performed. Medians are indicated in scatter plots as a solid black line. For all correlations, calculations were made by Spearman's rank correlation test.

is supported by our observation that plasma CXCL13 correlated with total circulating  $T_{FH}$  but not the effector  $T_{FH}$  subset previously shown to be associated with neutralization breadth in HIV-infected children (6). A potential caveat here is that our correlations between circulating  $T_{FH}$  and plasma CXCL13 levels

include HIV-ve controls, hence not limiting our observations to the dynamics in HIV infection. Interestingly, in adult viremic controllers, an inflammatory cytokine signature including CXCL13 and IP-10 was associated with the development of bnAbs (31). These data again demonstrate that interplay between

virus, immune activation and neutralization breadth in pediatric patients appears to be fundamentally distinct from adult infection (4). It is important to note, however, that CXCL13 may still have value as a marker of GC activity in the setting of childhood vaccination, which was not tested here.

The finding that plasma IL-5, but not the other classic Th2 cytokines IL-13 and IL-4, correlated with neutralization breadth within our cohort of HIV-infected children was unexpected. Impaired IL-5 production of T-cells has been previously described as a prognostic markers of disease progression in HIV-infected children (19). In this present study, we did not observe significant differences between the different clinical groups and IL-5 production of CD4 T-cells was very limited in general. It is therefore probable that other cell subsets are important sources of plasma IL-5, including type 2 innate lymphoid cells, mast cells, eosinophils and/or neutrophils (32, 33). Future work will be required to identify the source of IL-5 and may shed light on immune pathways that support antibody maturation. However, recently published data support an association between circulating CD8<sup>+</sup>CD57<sup>+</sup> T-cells in viremic controllers and neutralization breadth (34) and these cells were previously found to secrete high levels of IL-5 (35). In addition, IL-5 is known to be essential for antibody class switching in mice (36) and stimulates B-cell proliferation (37), particularly of germinal center B-cells (18). Finally, the fact that plasma levels of IL-5 correlated with neutralization breadth in HIV-infected children may also point to increased regulatory activity in these individuals. IL-5 promotes the expansion and survival of antigen specific T regulatory cells (Treg) (38), and treatment with recombinant IL-5 leads to an expansion of Treg and reduces pathology in experimental autoimmunity (39). Indeed, the fact that we observe no correlation between plasma IL-5 and circulating effector T<sub>FH</sub>, might suggest that the role for IL-5 does not relate to the germinal center activity. However, further work in an extended cohort of individuals or in the animal model is required to test these hypotheses. It would also be interesting to evaluate additional predictive plasma markers of neutralization breadth as has been done for adult infection (8, 10).

A biomarker which predicts GC activity, T<sub>FH</sub> activity, and neutralization breadth in the pediatric population would offer a powerful tool for vaccine development. Our results suggest that IL-5 is a potential candidate. In addition, exploration of the biology behind this association may improve our understanding of how broadly neutralizing antibodies develop in this key population.

## DATA AVAILABILITY

All relevant datasets generated for this study are included in the manuscript and/or the **Supplementary Files**.

## ETHICS STATEMENT

Informed consent was obtained from all adult study participants or from the caregivers of pediatric participants where

appropriate. Additionally, assent to participate in the study was given directly by children from the age of 6 and above. Studies were approved by the University of the Free State Ethics Committee, Bloemfontein; Biomedical Research Ethics Committee, University of KwaZulu-Natal, Durban; and Research Ethics Committee, University of Oxford.

## AUTHOR CONTRIBUTIONS

JR designed the study, conducted experimental work within the study, analyzed the data, and wrote the paper. JP conducted experimental work within the study and analyzed the data. PO conducted experimental work within the study. MM and EA recruited subjects and supervised the study cohort. AG performed statistical analyses. TN, LM, and PM supervised experimental work within the study. HK, PG, and AL supervised experimental work within the study, analyzed data, and wrote the paper. PG established research cohorts.

## FUNDING

AL is funded through the Wellcome Trust (grant 210662/Z/18/Z) and HHMI. PG is funded through the Wellcome Trust (grant 104748MA). HK is funded through the Wellcome Trust (grant 202485/Z/16/Z). PM is supported by the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation of South Africa (Grant 98341). This work was partially funded through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant DEL-15-006). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant 07752/Z/15/Z) and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.

## ACKNOWLEDGMENTS

We thank all children and their caregivers for their time and commitment to this study. We also thank the staff at the Ithembalabantu Clinic in Umlazi, Durban, for their essential support and all core staff members at the HIV Pathogenesis Programme who helped with patient recruitment and sample processing.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2019.01497/full#supplementary-material>

## REFERENCES

- Martinez DR, Permar SR, Fouda GG. Contrasting adult and infant immune responses to HIV infection and vaccination. *Clin Vaccine Immunol.* (2016) 23:84–94. doi: 10.1128/CVI.00565-15
- McGuire EP, Fong Y, Toote C, Cunningham CK, McFarland EJ, Borkowsky W, et al. HIV-exposed infants vaccinated with an MF59/Recombinant gp120 vaccine have higher-magnitude anti-V1V2 IgG responses than adults immunized with the same vaccine. *J Virol.* (2018) 92:e01070-17 doi: 10.1128/JVI.01070-17
- Goo L, Chohan V, Nduati R, Overbaugh J. Early development of broadly neutralizing antibodies in HIV-1-infected infants. *Nat Med.* (2014) 20:655–8. doi: 10.1038/nm.3565
- Muenchhoff M, Adland E, Karimanzira O, Crowther C, Pace M, Csala A, et al. Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. *Sci Transl Med.* (2016) 8:358ra125. doi: 10.1126/scitranslmed.aag1048
- Kollmann TR, Kampmann B, Mazmanian SK, Marchant A, Levy O. Protecting the newborn and young infant from infectious diseases: lessons from immune ontogeny. *Immunity.* (2017) 46:350–63. doi: 10.1016/j.immuni.2017.03.009
- Roider J, Maehara T, Ngoepe A, Ramsuran D, Muenchhoff M, Adland E, et al. High-frequency, functional HIV-specific t-follicular helper and regulatory cells are present within germinal centers in children but not adults. *Front Immunol.* (2018) 9:1975. doi: 10.3389/fimmu.2018.01975
- Havenar-Daughton C, Carnathan DG, Torrents de la Pena A, Pauthner M, Briney B, Reiss SM, et al. Direct probing of germinal center responses reveals immunological features and bottlenecks for neutralizing antibody responses to HIV env trimer. *Cell Rep.* (2016) 17:2195–209. doi: 10.1016/j.celrep.2016.10.085
- Cohen K, Altfeld M, Alter G, Stamatatos L. Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. *J Virol.* (2014) 88:13310–21. doi: 10.1128/JVI.02186-14
- Havenar-Daughton C, Lindqvist M, Heit A, Wu JE, Reiss SM, Kendrick K, et al. CXCL13 is a plasma biomarker of germinal center activity. *Proc Natl Acad Sci USA.* (2016) 113:2702–7. doi: 10.1073/pnas.1520112113
- Mabuka JM, Dugast AS, Muema DM, Reddy T, Ramlakhan Y, Euler Z, et al. Plasma CXCL13 but Not B cell frequencies in acute HIV infection predicts emergence of cross-neutralizing antibodies. *Front Immunol.* (2017) 8:1104. doi: 10.3389/fimmu.2017.01104
- Crotty S. Follicular helper CD4 T cells (TFH). *Annu Rev Immunol.* (2011) 29:621–63. doi: 10.1146/annurev-immunol-031210-101400
- Streeck H, D'Souza MP, Littman DR, Crotty S. Harnessing CD4(+) T cell responses in HIV vaccine development. *Nat Med.* (2013) 19:143–9. doi: 10.1038/nm.3054
- Crotty S. A brief history of T cell help to B cells. *Nat Rev Immunol.* (2015) 15:185–9. doi: 10.1038/nri3803
- Locci M, Havenar-Daughton C, Landais E, Wu J, Kroenke MA, Arlehamn CL, et al. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. *Immunity.* (2013) 39:758–69. doi: 10.1016/j.immuni.2013.08.031
- Schaerli P, Willmann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. *J Exp Med.* (2000) 192:1553–62. doi: 10.1084/jem.192.11.1553
- Bekele Y, Yibeltal D, Bobosha K, Andargie TE, Lemma M, Gebre M, et al. T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART. *Sci Rep.* (2017) 7:8956. doi: 10.1038/s41598-017-09165-6
- Locci M, Wu JE, Arumemi F, Mikulski Z, Dahlberg C, Miller AT, et al. Activin A programs the differentiation of human TFH cells. *Nat Immunol.* (2016) 17:976–84. doi: 10.1038/ni.3494
- Rabinowitz JL, Tsiagbe VK, Nicknam MH, Thorbecke GJ. Germinal center cells are a major IL-5-responsive B cell population in peripheral lymph nodes engaged in the immune response. *J Immunol.* (1990) 145:2440–7.
- Resino S, Sanchez-Ramon S, Bellon JM, Jimenez JL, Munoz-Fernandez MA. Impaired interleukin-5 (IL-5) production by T cells as a prognostic marker of disease progression in human immunodeficiency virus type 1 (HIV-1)-infected children. *Eur Cytokine Netw.* (2001) 12:253–9.
- Team RC. *R: A Language and Environment for Statistical Computing.* Vienna: R Foundation for Statistical Computing (2018).
- McCullagh PA. *Generalized Linear Models, 2nd ed.* London: Chapman & Hall (1989). doi: 10.1007/978-1-4899-3242-6\_1
- Hastie TJ, Tibshirani, RJ. *Generalized Additive Models.* New York, NY/Boca Raton, FL: Chapman & Hall/CRC (1990).
- Widney DP, Breen EC, Boscardin WJ, Kitchen SG, Alcantar JM, Smith JB, et al. Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. *J Interferon Cytokine Res.* (2005) 25:702–6. doi: 10.1089/jir.2005.25.702
- Bekele Y, Lemma M, Bobosha K, Yibeltal D, Nasi A, Gebre M, et al. Homing defects of B cells in HIV-1 infected children impair vaccination responses. *Vaccine.* (2019) 37:2348–55. doi: 10.1016/j.vaccine.2019.03.027
- Doria-Rose NA. HIV neutralizing antibodies: clinical correlates and implications for vaccines. *J Infect Dis.* (2010) 201:981–3. doi: 10.1086/651143
- Sansonno D, Tucci FA, Troiani L, Lauletta G, Montrone M, Conteduca V, et al. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. *Blood.* (2008) 112:1620–7. doi: 10.1182/blood-2008-02-137455
- Lee HT, Shiao YM, Wu TH, Chen WS, Hsu YH, Tsai SF, et al. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. *J Rheumatol.* (2010) 37:45–52. doi: 10.3899/jrheum.090450
- Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. *J Clin Immunol.* (2010) 30:45–52. doi: 10.1007/s10875-009-9325-5
- Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. *Br J Cancer.* (2008) 99:930–8. doi: 10.1038/sj.bjc.6604621
- Mehraj V, Ramendra R, Isnard S, Dupuy FP, Lebouche B, Costiniuk C, et al. CXCL13 as a biomarker of immune activation during early and chronic HIV infection. *Front Immunol.* (2019) 10:289. doi: 10.3389/fimmu.2019.00289
- Dugast AS, Arnold K, Lofano G, Moore S, Hoffner M, Simek M, et al. Virus-driven inflammation is associated with the development of bNAbs in spontaneous controllers of HIV. *Clin Infect Dis.* (2017) 64:1098–104. doi: 10.1093/cid/cix057
- Anunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. *J Allergy Clin Immunol.* (2015) 135:626–35. doi: 10.1016/j.jaci.2014.11.001
- Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, Hattori Y, et al. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. *J Immunol.* (2012) 188:703–13. doi: 10.4049/jimmunol.1101270
- Palmer CD, Romero-Tejeda M, Scully EP, Lockhart A, Seaman MS, Goldenthal A, et al. Increased frequencies of CD8(+)CD57(+) T cells are associated with antibody neutralization breadth against HIV in viraemic controllers. *J Int AIDS Soc.* (2016) 19:21136. doi: 10.7448/IAS.19.1.21136
- Chong LK, Aicheler RJ, Llewellyn-Lacey S, Tomasec P, Brennan P, Wang EC. Proliferation and interleukin 5 production by CD8hi CD57+ T cells. *Eur J Immunol.* (2008) 38:995–1000. doi: 10.1002/eji.200737687
- Mandler R, Chu CC, Paul WE, Max EE, Snapper CM. Interleukin 5 induces S mu-S gamma 1 DNA rearrangement in B cells activated with dextran-anti-IgD antibodies and interleukin 4: a three component model for Ig class switching. *J Exp Med.* (1993) 178:1577–86. doi: 10.1084/jem.178.5.1577

37. Takatsu K, Tominaga A, Harada N, Mita S, Matsumoto M, Takahashi T, et al. T cell-replacing factor (TRF)/interleukin 5 (IL-5): molecular and functional properties. *Immunol Rev.* (1988) 102:107–35. doi: 10.1111/j.1600-065X.1988.tb00743.x
38. Hall BM, Tran GT, Verma ND, Plain KM, Robinson CM, Nomura M, et al. Do natural T regulatory cells become activated to antigen specific T regulatory cells in transplantation and in autoimmunity? *Front Immunol.* (2013) 4:208. doi: 10.3389/fimmu.2013.00208
39. Tran GT, Hodgkinson SJ, Carter NM, Verma ND, Plain KM, Boyd R, et al. IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity. *Blood.* (2012) 119:4441–50. doi: 10.1182/blood-2011-12-396101

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Roider, Porterfield, Ogongo, Muenchhoff, Adland, Groll, Morris, Moore, Ndung'u, Kløverpris, Goulder and Leslie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.